Agerafenib

Agerafenib was originally discovered by a company called Daiichi Sankyo (then called Ambit Biosciences) and Teva Pharmaceuticals (then called Cephalon) during a research program. The chemical was originally named "CEP-32496" before being renamed to "RXDX 105" in 2015. == Characteristics ==

Agerafenib's chemical formula consists of 24 carbon atoms, 22 hydrogen atoms, 3 fluorine atoms, 5 nitrogen atoms and 5 oxygen atoms. The chemical's molar mass is 517.465 g/mol, and the monoisotopic mass is 517.157303 g/mol. It appears as a white to off-white crystalline powder in room temperature. Agerafenib has 5 hydrogen bond acceptors and 2 hydrogen bond donors. It has an partition coefficient of 4.35. It has 10 rotatable bonds and a topological polar surface area of 120.63. It does this due to its strong cytotoxicity to cells containing it. The drug is shown to be most effective in humans in doses between 30 milligrams and 100 milligrams. ==References==